home > drugs a-z list > osmoprep (sodium phosphate monobasic monohydrate and sodium phosphate dibasic anhydrous) drug center > osmoprep (sodium phosphate monobasic monohydrate and sodium phosphate dibasic anhydrous) drug - clinical pharmacology

OsmoPrep (sodium phosphate monobasic monohydrate and sodium phosphate dibasic anhydrous) Tablets, a dosing regimen containing 48 grams of sodium phosphate (32 tablets), induces diarrhea, which effectively cleanses the entire colon. Each administration has a purgative effect for approximately 1 to 3 hours. The primary mode of action is thought to be through the osmotic effect of sodium, causing large amounts of water to be drawn into the colon, promoting evacuation.

Pharmacokinetics

Pharmacokinetic studies with OsmoPrep (sodium phosphate monobasic monohydrate and sodium phosphate dibasic anhydrous) have not been conducted. However, the following pharmacokinetic study was conducted with Visicol® tablets which contain the same active ingredients (sodium phosphate) as OsmoPrep (sodium phosphate monobasic monohydrate and sodium phosphate dibasic anhydrous) . In addition, Visicol is administered at a dose that is 25% greater than the OsmoPrep (sodium phosphate monobasic monohydrate and sodium phosphate dibasic anhydrous) dose.

An open-label pharmacokinetic study of Visicol in healthy volunteers was performed to determine the concentration-time profile of serum inorganic phosphorus levels after Visicol administration. All subjects received the approved Visicol dosing regimen (60 grams of sodium phosphate with a total liquid volume of 3.6 quarts) for colon cleansing. A 30 gram dose (20 tablets given as 3 tablets every 15 minutes with 8 ounces of clear liquids) was given beginning at 6 PM in the evening. The 30 gram dose (20 tablets given as 3 tablets every 15 minutes with 8 ounces of clear liquids) was repeated the following morning beginning at 6 AM.

Twenty-three healthy subjects (mean age 57 years old; 57% male and 43% female; and 65% Hispanic, 30% Caucasian, and 4% African-American) participated in this pharmacokinetic study. The serum phosphorus level rose from a mean (± standard deviation) baseline of 4.0 (± 0.7) mg/dL to 7.7 (± 1.6 mg/dL), at a median of 3 hours after the administration of the first 30-gram dose of sodium phosphate tablets (see Figure 1). The serum phosphorus level rose to a mean of 8.4 (± 1.9) mg/dL, at a median of 4 hours after the administration of the second 30-gram dose of sodium phosphate tablets. The serum phosphorus level remained above baseline for a median of 24 hours after the administration of the initial dose of sodium phosphate tablets (range 16 to 48 hours).

Figure 1 : Mean (± standard deviation) serum phosphorus concentrations

The upper (4.5 mg/dL) and lower (2.6 mg/dL) reference limits for serum phosphate are represented by solid bars.

Special Populations

Renal Insufficiency

The effect of renal dysfunction on the pharmacokinetics of OsmoPrep (sodium phosphate monobasic monohydrate and sodium phosphate dibasic anhydrous) Tablets has not been studied. Since the inorganic form of phosphate in the circulating plasma is excreted almost entirely by the kidneys, patients with renal disease may have difficulty excreting a large phosphate load. Thus, OsmoPrep Tablets should be used with caution in patients with impaired renal function (see WARNINGS).

Hepatic Insufficiency

OsmoPrep (sodium phosphate monobasic monohydrate and sodium phosphate dibasic anhydrous) Tablets have not been investigated in patients with hepatic failure.

Geriatric

In a single pharmacokinetic study of sodium phosphate tablets, which included 6 elderly volunteers, plasma half-life increased two-fold in subjects > 70 years of age compared to subjects < 50 years of age (3 subjects and 5 subjects, respectively).

Gender

No difference in serum phosphate AUC values were observed in the single pharmacokinetic study conducted with sodium phosphate tablets in 13 male and 10 female healthy volunteers.

Clinical Studies

The colon cleansing efficacy and safety of OsmoPrep (sodium phosphate monobasic monohydrate and sodium phosphate dibasic anhydrous) was evaluated in 2 randomized, investigator-blinded, actively controlled, multicenter, U.S. trials in patients scheduled to have an elective colonoscopy. The trials consisted of a dose ranging and a confirmatory phase 3 study.

In the phase 3 trial, patients were randomized into one of the following three sodium phosphate treatment groups: 1) Visicol containing 60 grams of sodium phosphate given in split doses (30 grams in the evening before the colonoscopy and 30 grams on the next day) with at least 3.6 quarts of clear liquids; 2) OsmoPrep (sodium phosphate monobasic monohydrate and sodium phosphate dibasic anhydrous) containing 60 grams of sodium phosphate given in split doses (30 grams in the evening before the colonoscopy and 30 grams on the next day) with 2.5 quarts of clear liquids; and 3) OsmoPrep (sodium phosphate monobasic monohydrate and sodium phosphate dibasic anhydrous) containing 48 grams of sodium phosphate (30 grams in the evening before the colonoscopy and 18 grams on the next day) with 2 quarts of clear liquids. Patients were instructed to eat a light breakfast before noon on the day prior to the colonoscopy and then were told to drink only clear liquids after noon on the day prior to the colonoscopy.

The primary efficacy endpoint was the overall colon cleansing response rate in the 4-point Colonic Contents Scale. Response was defined as a rating of “excellent” or “good” on the 4-point scale as determined by the blinded colonoscopist. This phase 3 study was planned to assess the non-inferiority of the two OsmoPrep (sodium phosphate monobasic monohydrate and sodium phosphate dibasic anhydrous) groups compared to the Visicol group.

The efficacy analysis included 704 adult patients who had an elective colonoscopy. Patients ranged in age from 21 to 89 years old (mean age 56 years old) with 55% female and 45% male patients. Race was distributed as follows: 87% Caucasian, 10% African American, and 3% other race.

The OsmoPrep (sodium phosphate monobasic monohydrate and sodium phosphate dibasic anhydrous) 60 gram and 48 gram treatment groups demonstrated noninferiority compared to Visicol. See Table 1 for the results.

Table 1: Phase 3 Study – Overall Colon Content Cleansing Response Rates¹

Electrolyte Changes

In the OsmoPrep (sodium phosphate monobasic monohydrate and sodium phosphate dibasic anhydrous) clinical studies, expected serum electrolyte changes (including phosphate, calcium, potassium, and sodium levels) have been observed in patients taking OsmoPrep (sodium phosphate monobasic monohydrate and sodium phosphate dibasic anhydrous) . In the overwhelming majority of patients, electrolyte abnormalities were not associated with any adverse events.

In the OsmoPrep (sodium phosphate monobasic monohydrate and sodium phosphate dibasic anhydrous) phase 3 study, 96%, 96%, and 93% of patients who took 60 grams of Visicol, 60 grams of OsmoPrep (sodium phosphate monobasic monohydrate and sodium phosphate dibasic anhydrous) , and 48 grams of OsmoPrep (sodium phosphate monobasic monohydrate and sodium phosphate dibasic anhydrous) , respectively, developed hyperphosphatemia (defined as phosphate level > 5.1 mg/dL) on the day of the colonoscopy. In this study, patients who took 60 grams of Visicol, 60 grams of OsmoPrep (sodium phosphate monobasic monohydrate and sodium phosphate dibasic anhydrous) , and 48 grams of OsmoPrep (sodium phosphate monobasic monohydrate and sodium phosphate dibasic anhydrous) had baseline mean phosphate levels of 3.5, 3.5, and 3.6 mg/dL and subsequently developed mean phosphate levels of 7.6, 7.9, and 7.1 mg/dL, respectively, on the day of the colonoscopy.

In the OsmoPrep (sodium phosphate monobasic monohydrate and sodium phosphate dibasic anhydrous) phase 3 study, 20%, 22%, and 18% of patients who took 60 grams of Visicol, 60 grams of OsmoPrep (sodium phosphate monobasic monohydrate and sodium phosphate dibasic anhydrous) , and 48 grams of OsmoPrep (sodium phosphate monobasic monohydrate and sodium phosphate dibasic anhydrous) , respectively, developed hypokalemia (defined as a potassium level < 3.4 mEq/L) on the day of the colonoscopy. In this study, patients who took 60 grams of Visicol, 60 grams of OsmoPrep (sodium phosphate monobasic monohydrate and sodium phosphate dibasic anhydrous) , and 48 grams of OsmoPrep (sodium phosphate monobasic monohydrate and sodium phosphate dibasic anhydrous) all had baseline potassium levels of about 4.3 mEq/L and then developed a mean potassium level of 3.7 mEq/L on the day of the colonoscopy.

In the OsmoPrep (sodium phosphate monobasic monohydrate and sodium phosphate dibasic anhydrous) phase 3 trial, several patients on all three sodium phosphate regimens developed hypocalcemia and hypernatremia that did not require treatment.

Last reviewed on RxList: 9/15/2009
This monograph has been modified to include the generic and brand name in many instances.